Compare STGW & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STGW | ABCL |
|---|---|---|
| Founded | 1980 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 2006 | 2020 |
| Metric | STGW | ABCL |
|---|---|---|
| Price | $6.89 | $5.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $8.39 | ★ $8.40 |
| AVG Volume (30 Days) | 1.4M | ★ 6.5M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,909,000,000.00 | $75,128,000.00 |
| Revenue This Year | $13.27 | N/A |
| Revenue Next Year | $4.07 | $21.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 2.39 | ★ 160.56 |
| 52 Week Low | $4.29 | $2.75 |
| 52 Week High | $7.52 | $6.79 |
| Indicator | STGW | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 57.25 | 49.96 |
| Support Level | $4.94 | $3.42 |
| Resistance Level | $7.02 | $5.63 |
| Average True Range (ATR) | 0.31 | 0.54 |
| MACD | -0.00 | -0.12 |
| Stochastic Oscillator | 53.94 | 9.83 |
Stagwell Inc is a challenger network using AI to deliver marketing and advertising solutions to its clients. It operates in five reportable segments: Marketing Services, Digital Transformation, Media and Commerce, Communications, and The Marketing Cloud. Maximum revenue is generated from the Marketing Services segment, which offers social media solutions, designs breakthrough brand campaigns, and creates immersive experiential marketing programs and social engagement strategies, helping clients connect with audiences across digital platforms. The various brands operating under this segment include 72 and Sunny, Anomaly, NRG, Harris Insights, TEAM, and Movers & Shaker. Geographically, the company generates maximum revenue from the United States, followed by the UK and other countries.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.